GDS-SW (09698) intends to privately place $300 million of Series B convertible preferred stock to Huatai Capital.
Wanka Data-SW (09698) announced a private placement of 300 million US dollars of Series B convertible preferred stocks to a Chinese institutional investor, Huatai Capital Investment Limited. Wanka Data will use the proceeds from the private placement to expand data center capacity and for general corporate purposes.
The announcement of GDS-SW (09698) states that $300 million of Series B Convertible Preferred Stock will be privately placed to a Chinese institutional investor, Huatai Capital Investment Co., Ltd. GDS Global will use the proceeds from the private placement to expand data center capacity and for general corporate purposes.
The cumulative annual dividend rate for the convertible preferred stock for the first six years shall not be less than 3.75%, and from the sixth year onwards, the minimum dividend rate will increase to 6.75% with a 50 basis point increase every quarter. The conversion price is approximately $54.43 per GDS American Depositary Share, representing a premium of 17.5% over the closing price in Hong Kong as of January 30, 2026.
The Board of Directors believes that the private placement is beneficial for the company and shareholders as it strengthens the relationship with one of China's leading financial institutions, allowing the company to further enhance the "control" of Chinese nationals in terms of voting rights, and continue to serve its major clients in mainland China.
Related Articles

New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


